Q-omics provides the consensus-scored RASGRF2-AS1 profile across patient tissues and cancer cell-line models. RASGRF2-AS1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, RASGRF2-AS1 is differentially expressed in 12, with the highest sampling consensus in KIRP. Additionally, RASGRF2-AS1 RNA expression shows 15,502 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight LIHC, KIRP, and BRCA as cancer lineages where RASGRF2-AS1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RASGRF2-AS1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RASGRF2-AS1 survival associations across molecular data types. RASGRF2-AS1 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RASGRF2-AS1 RNA expression–survival associations across cancer types. High RASGRF2-AS1 expression shows unfavorable associations in KICH, but favorable associations in LIHC, SKCM, ESCA, READ and MESO. The LIHC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify LIHC as the clearest survival context for RASGRF2-AS1 RNA expression.
This table summarizes RASGRF2-AS1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for RASGRF2-AS1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RASGRF2-AS1 shows lower tumor expression in KIRP, THCA, BLCA and BRCA and higher tumor expression in LIHC and LUAD. The KIRP box plot shows higher RASGRF2-AS1 RNA expression in normal versus tumor tissue (log2 FC = −0.223, t-test p < 0.001).
This table shows molecular features associated with RASGRF2-AS1 in patient tissues and cancer cell lines. In patient samples, RASGRF2-AS1 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set.
